Emergent Biosolutions (EBS) : Traders are bullish on Emergent Biosolutions (EBS) as it has outperformed the S&P 500 by a wide margin of 12.52% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.31%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.25% in the last 1 week, and is up 16.3% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 7.62% and the 50-Day Moving Average is 7.77%. Emergent BioSolutions, Inc. has dropped 13.32% during the last 3-month period . Year-to-Date the stock performance stands at -16.55%.
Emergent Biosolutions (NYSE:EBS): stock turned positive on Friday. Though the stock opened at $32.92, the bulls momentum made the stock top out at $33.67 level for the day. The stock recorded a low of $32.0259 and closed the trading day at $33.39, in the green by 1.64%. The total traded volume for the day was 944,463. The stock had closed at $32.85 in the previous days trading.
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and Governments to address medical needs and emerging health threats. The Companys two operating divisions include Biodefense and Biosciences. The Companys Biodefense division is a pharmaceutical business focused on countermeasures that address CBRNE (Chemical, Biological, Radiological, Nuclear and Explosives) threats. The Biodefense divisions marketed products are BioThrax; BAT; Anthrasil; VIGIV, and RSDL. The Biodefense division investigational stage product candidates include NuThrax, PreviThrax, GC-072 and other biodefense product candidates. The Biosciences divisions marketed products are WinRho SDF, HepaGam B, VARIZIG and episil. The Biosciences division investigational stage product candidates include IXINITY, ES414 and otlertuzumab.